Regeneron Pharmaceuticals (REGN) Income from Non-Controlling Interests (2017 - 2019)

Regeneron Pharmaceuticals' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$1.0 million for Q1 2019.

• On a quarterly basis, Income from Non-Controlling Interests fell 171.43% year-over-year to -$1.0 million in Q1 2019; TTM through Mar 2019 was -$1.8 million, a 181.82% decrease from a year earlier, with the FY2018 full-year figure at $700000.0, down 12.5% from the prior year.
• Income from Non-Controlling Interests improved to -$1.0 million in Q1 2019 per REGN's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $1.4 million in Q1 2018 and bottomed at -$1.7 million in Q4 2018.
• The 3-year median for Income from Non-Controlling Interests is $164000.0 (2017), against an average of $50000.0.
• Biggest YoY gain for Income from Non-Controlling Interests was 14900.0% in 2018; the steepest drop was 320.78% in 2018.
• Year by year, Income from Non-Controlling Interests stood at $770000.0 in 2017, then plunged by 320.78% to -$1.7 million in 2018, then jumped by 41.18% to -$1.0 million in 2019.
• Per Business Quant, the three latest REGN Income from Non-Controlling Interests figures stand at -$1.0 million (Q1 2019), -$1.7 million (Q4 2018), and $300000.0 (Q3 2018).